Breast Cancer Research Program

项目004 -乳腺癌研究 项目总结/摘要 乳腺癌研究计划（BC）非常重视高影响力，协作，多方面的研究。 学科和机制研究，包括乳腺上皮细胞和分子生物学、遗传学 基因组学、免疫治疗、基础科学驱动的转化和临床研究、创新的临床试验 和分子流行病学。满足范德比尔特-英格拉姆癌症中心（VICC）的需求 该方案的具体目标是： 目标1。为了发现特定乳腺癌亚型的预测性生物标志物和耐药机制， 并将这些发现转化为临床试验。 目标2.减少乳腺癌的健康差异，重点关注基因组学，肥胖，医疗保健的影响 使用和生活方式对乳腺癌预后的影响。 目标3。优化乳腺癌的护理服务，重点是传播新数据的新方法， 尖端技术以及实施最新指南和批准的乳腺癌治疗方法， 癌 来自BC和其他计划的持续基础和转化发现为新的研究提供了稳定的渠道。 采用创新方法的干预性试验。这些发现和转化为临床研究是 通过全球系统性液体活检（无细胞DNA [cfDNA]）和所有阶段的组织储存方案进行增强 和乳腺癌的类型。这些试验是强大的干预组合的一部分， 基因组学驱动的试验和干预性治疗试验的累积（17%的患者），这是可比的 与过去和当前项目期间的全国平均水平（16%）相比。BC也有广泛的科学 与多个国家和国际机构以及财团和制药公司合作。 有来自11个部门和三所学校的27名项目成员，共获得670万美元的同行评审 资金和NCI占43%（290万美元），包括卓越研究专业计划（SPORE） 在乳腺癌中。成员的专业知识包括细胞信号，分子生物学，乳腺病理学，遗传学， 基因组分析，生物信息学，医学，外科和放射肿瘤学，临床试验设计，流行病学和 生活质量研究。在396份出版物中，20%是方案内出版物，34%是方案间出版物。 成员还与其他NCI指定的癌症中心的研究人员合作发表了185篇论文。

PROJECT 004 – BREAST CANCER RESEARCH PROGRAM PROJECT SUMMARY/ABSTRACT The Breast Cancer Research Program (BC) has a strong emphasis on high-impact, collaborative, multi- disciplinary and mechanism-based research encompassing breast epithelial cell and molecular biology, genetics and genomics, immunotherapy, basic science-driven translational and clinical research, innovative clinical trials and molecular epidemiology. To address the needs of the Vanderbilt-Ingram Cancer Center (VICC) catchment area, Specific Aims of the Program are: Aim 1. To discover predictive biomarkers and mechanisms of drug resistance in specific breast cancer subtypes, and translate these findings to clinical trials. Aim 2. To reduce health disparities in breast cancer, focusing on the impact of genomics, obesity, healthcare use and lifestyle on breast cancer outcomes. Aim 3. To optimize care delivery in breast cancer, focusing on novel methods for dissemination of new data and cutting-edge technologies as well as implementation of recent guidelines and approved therapies for breast cancer Ongoing basic and translational discoveries from BC and other programs provide a steady pipeline for novel interventional trials with innovative approaches. These discoveries and translation to clinical studies are enhanced by a global systematic liquid biopsy (cell-free DNA [cfDNA]) and tissue repository protocol for all stages and types of breast cancer. These trials are part of a robust interventional portfolio, with an abundance of genomically-driven trials and accruals to interventional treatment trials (17% of our patients) which is comparable to the national average (16%) for the past and current project periods. BC also has extensive scientific collaborations with multiple national and international institutions, as well as consortia and pharma. There are 27 program members from 11 departments and three schools with $6.7M in total peer-reviewed funding and NCI making up 43% ($2.9M), including a Specialized Programs of Research Excellence (SPORE) in Breast Cancer. Member expertise includes cellular signaling, molecular biology, breast pathology, genetics, genomic profiling, bioinformatics, medical, surgical and radiation oncology, clinical trial design, epidemiology and quality of life studies. Out of 396 publications, 20% are intra-programmatic and 34% are inter-programmatic. Members also have 185 collaborative publications with investigators at other NCI-designated cancer centers.